Drug Trial Radar · NCT06026891
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
498
Planned (sponsor's estimate)
Start
Jan 13, 2024
Primary completion
Jun 11, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
Conditions
- Atopic Dermatitis
Interventions
MG-K10/PlaceboDrug
MG-K10 Humanized Monoclonal Antibody Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of subjects achieving EASI-75Time frame: 16 weeks
- Proportions of subjects achieving IGA score of 0/1 point and a decrease of ≥ 2Time frame: 16weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.